ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Operating income

Astellas Pharma Inc. (4503)

Market cap
¥4.72T
P/E ratio
18.7x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating income (Million JPY)YoY (%)
Mar 31, 202541,039+60.82%
Mar 31, 202425,518-80.82%
Mar 31, 2023133,029-14.55%
Mar 31, 2022155,686+14.43%
Mar 31, 2021136,051-44.24%
Mar 31, 2020243,991+0.03%
Mar 31, 2019243,912-1908.09%
Mar 31, 2018-13,490-186.47%
Mar 31, 201715,600+179.07%
Mar 31, 20165,590-87.39%
Mar 31, 201544,333

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat